204 related articles for article (PubMed ID: 37407805)
1. The role of the mitochondrial ribosomal protein family in detecting hepatocellular carcinoma and predicting prognosis, immune features, and drug sensitivity.
Zhao JW; Zhao WY; Cui XH; Xing L; Shi JC; Yu L
Clin Transl Oncol; 2024 Feb; 26(2):496-514. PubMed ID: 37407805
[TBL] [Abstract][Full Text] [Related]
2. Expression analysis of mammalian mitochondrial ribosomal protein genes.
Cheong A; Lingutla R; Mager J
Gene Expr Patterns; 2020 Dec; 38():119147. PubMed ID: 32987154
[TBL] [Abstract][Full Text] [Related]
3. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy.
Long S; Chen Y; Wang Y; Yao Y; Xiao S; Fu K
Cancer Med; 2023 Jan; 12(2):2134-2147. PubMed ID: 35841206
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
5. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognosis analysis of mitochondrial ribosomal protein family in breast cancer.
Lin X; Guo L; Lin X; Wang Y; Zhang G
Sci Rep; 2022 Jun; 12(1):10658. PubMed ID: 35739158
[TBL] [Abstract][Full Text] [Related]
7. The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.
Shen X; Hu B; Xu J; Qin W; Fu Y; Wang S; Dong Q; Qin L
Cancer Biol Med; 2020 Nov; 17(4):937-952. PubMed ID: 33299645
[TBL] [Abstract][Full Text] [Related]
8. MRPS31 loss is a key driver of mitochondrial deregulation and hepatocellular carcinoma aggressiveness.
Min S; Lee YK; Hong J; Park TJ; Woo HG; Kwon SM; Yoon G
Cell Death Dis; 2021 Nov; 12(11):1076. PubMed ID: 34772924
[TBL] [Abstract][Full Text] [Related]
9. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
11. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
Xu L; Zheng Q; Liu W
BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
[TBL] [Abstract][Full Text] [Related]
12. Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis.
Tang Y; Zhang Y; Hu X
Biomed Res Int; 2020; 2020():4251761. PubMed ID: 33376723
[TBL] [Abstract][Full Text] [Related]
13. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.
Deng M; Fang L; Li SH; Zhao RC; Mei J; Zou JW; Wei W; Guo RP
Mutagenesis; 2021 Oct; 36(5):369-379. PubMed ID: 34467992
[TBL] [Abstract][Full Text] [Related]
14. Life span-associated ferroptosis-related genes identification and validation for hepatocellular carcinoma patients as hepatitis B virus carriers.
Weng W; Zhang D; Li S
J Clin Lab Anal; 2023 Jul; 37(13-14):e24930. PubMed ID: 37461802
[TBL] [Abstract][Full Text] [Related]
15. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
17. High Expression of Ten Eleven Translocation 1 Is Associated with Poor Prognosis in Hepatocellular Carcinoma.
Wen H; Ji T; Lin L; Cheng N; Zhu K; Cao L
Mediators Inflamm; 2023; 2023():2664370. PubMed ID: 37181808
[TBL] [Abstract][Full Text] [Related]
18. Mining prognostic markers of Asian hepatocellular carcinoma patients based on the apoptosis-related genes.
Yan J; Cao J; Chen Z
BMC Cancer; 2021 Feb; 21(1):175. PubMed ID: 33602168
[TBL] [Abstract][Full Text] [Related]
19. Identification and analysis of necroptosis-associated signatures for prognostic and immune microenvironment evaluation in hepatocellular carcinoma.
Lu J; Yu C; Bao Q; Zhang X; Wang J
Front Immunol; 2022; 13():973649. PubMed ID: 36081504
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.
Chen J; Gao G; Zhang Y; Dai P; Huang Y
BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
